Evidence map›Paper›PMID 32944834›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.

M S A Amin, O Brunckhorst, C Scott, D Wrench, M Gleeson, M Kazmi, K Ahmed

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

M S A AminMRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, SE1 9RT, UK.ORCID http://orcid.org/0000-0002-5289-8890
O BrunckhorstMRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, SE1 9RT, UK.
C ScottMRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, SE1 9RT, UK.
D WrenchDepartment of Haematology, Guy's Hospital, London, UK.
M GleesonDepartment of Haematology, Guy's Hospital, London, UK.
M KazmiDepartment of Haematology, Guy's Hospital, London, UK.
K AhmedMRC Centre for Transplantation, Guy's Hospital Campus, King's College London, King's Health Partners, London, SE1 9RT, UK. kamran.ahmed@kcl.ac.uk.
Guy's Hospital · GBKings Health Partners · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConsidering the increased cancer patient survivorship, the focus is now on addressing the impacts of treatment on quality of life. In young people, altered reproductive function is a major issue and its effects in young males are largely neglected by novel research. To improve clinician awareness, we systematically reviewed side effects of chemotherapy for Hodgkin lymphoma (HL) in young males.

methodsThe review was prospectively registered (PROSPERO N. CRD42019122868). Three databases (Medline via PUBMED, SCOPUS, and Cochrane Library) were searched for studies featuring males aged 13-51-years who underwent chemotherapy for HL using ABVD (Adriamycin® (doxorubicin), bleomycin, vinblastine, and dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) regimens. These chemotherapy regimens were compared against each other using sperm characteristics, FSH, and inhibin B levels to measure fertility levels.

resultsData were extracted from five studies featuring 1344 patients. 6 months post-ABVD saw marked deterioration in sperm count, further reduced by more cycles (P = 0.05). Patients treated with BEACOPP rather than ABVD were more prone to oligospermia. Receiving fewer cycles of both regimens increased the likelihood of sperm production recovering. Patients treated with 6-8 cycles of BEACOPP did not recover spermiogenesis.

conclusionsABVD and BEACOPP regimens significantly reduce fertility function to varying effects depending on treatment duration. ABVD temporarily causes significant reductions in male fertility, whereas BEACOPP's effects are more permanent. Therefore, clinicians should discuss fertility preservation with male patients receiving infertility-inducing gonadotoxic therapy. Further high-quality studies are required to more adequality describe the risk to fertility by chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideDacarbazineDoxorubicinEtoposideFertilityHodgkin DiseaseHumansInfertility, MaleMalePrednisoneProcarbazineVinblastineVincristineBleomycinCyclophosphamideDacarbazineDoxorubicinEtoposidePrednisoneProcarbazineVinblastineVincristineABVDBEACOPPFertilityHodgkin lymphomaYoung males

Identifiers

PMID32944834
PMCPMC8084804
OpenAlexW3087148765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.